Status:
COMPLETED
Study of Microcirculatory Effects of Bevacizumab in Patients Treated for Metastatic Colon Cancer or Glioblastoma
Lead Sponsor:
Centre Georges Francois Leclerc
Conditions:
Metastatic Colorectal Cancer
Glioblastoma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The treatment of the most common cancers (colon, breast, lung, liver and kidney) has recently added a new therapeutic class known as the "anti-angiogenic". It was born from a better understanding of t...
Eligibility Criteria
Inclusion
- Age ≥ 18 years
- signed informed Consent
- Medical Examination
- Patients with metastatic colorectal cancer
- Patients with a glioblastoma
- patient to receive treatment with bevacizumab not yet started
- MRI for patients with glioblastoma or scanner TAP for patients carrying a metastatic colon cancer performed within 3 weeks before inclusion.
Exclusion
- Bevacizumab already initiated or history of antiangiogenic treatment
- Inability legal (persons deprived of liberty or under guardianship)
- Pregnant or lactating women
- Can not sign consent or unable to undergo medical follow up for geographical, social or psychological reasons
- Patients not covered by Medicare including CMU
- Estimated life of over 3 months
Key Trial Info
Start Date :
May 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2015
Estimated Enrollment :
47 Patients enrolled
Trial Details
Trial ID
NCT01810744
Start Date
May 1 2013
End Date
May 1 2015
Last Update
March 15 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Georges François Leclerc
Dijon, France, 21079